多西他赛联合替吉奥治疗复发转移性乳腺癌的临床 .doc

多西他赛联合替吉奥治疗复发转移性乳腺癌的临床分析 谢家印，向大开，王 东,杜 佳，邹 华，罗 维 400042重庆，第三军医大学大坪医院野战外科研究所肿瘤中心 [摘要]目的 观察和评价国产多西他赛（艾素）联合替吉奥治疗复发转移性乳腺癌的临床疗效和毒副反应。方法 回顾性分析我院自2008年1月至2010后12月经多西他赛联合替吉奥治疗的50例复发转移性乳腺癌患者。结果 50例患者CR3例，PR14例，SD16例，PD17例，ORR38%，CBR48%。中位生存期为415 d，中位疾病进展时间为163 d。16例早期阶段（首次或第二次化疗）和34例后期阶段（三次化疗以上）患者其ORR分别为50% 、26.5%，CBR为 68.8% 、 38.2%，后者相比较两组有统计学意义（P 0.05）。31例曾用过多西他赛联合卡培他滨治疗的患者其ORR、CBR为19.4%、32.3%。毒副反应主要是粒细胞减少，Ⅳ级严重不良反应仅占8%。结论 多西他赛联合替吉奥治疗复发转移性乳腺癌疗效好，毒副作用低，患者生活质量高，尤其用在早期阶段具有明显优势。 [关键词] 转移性乳腺癌；多西他赛；替吉奥 [中图法分类号] [文献标志码] A Clinical Analysis of combination of docetaxel and S-1 in the patients with metastatic breast cancer Xie Jiayin,Xiang Dakai,Wang Dong，Du Jia,Zhou Huauo Wei Cancer Center，Institute of Surgery Research，Daping Hospital，Third Military Medical University，Chongqing 400042，China analyze the efficacy and safety of combination of docetaxel and S-1 in the patients with metastatic breast cancer MBC .Methods Fifty patients with MBC who had been administered docetaxel and S-1,between January 2008 and December 2010 in our hospital were retrospectively reviewed.Results The overall response rate ORR ,clinical benefit rate CBR ,median time to treatment failure and overall survival of the fifty patients were 38%,48%,163 days and 415 days.Among the 16 patients in the first or the second line and the 34 patients in the the third and later line,ORR were 50% and 26.5% respectively,but CBR in the first or the second line were significantly higher than that of patients in the third and later line 68.8% vs 38.2%,P 0.05 ..For the 31 patients who were treated with docetaxel and capecitabine,ORR and CBR were 19.4%,32.3% respectively.The majority of toxicity were granulopenia.Grade 4 events occurred only 8%.Conclusion Docetaxel and S-1 is well-tolerated and safe by patients with MBC,promising a therapy while maintaining their quality of life..When applied in the early stage of MBC in particular,the agent promises a very effective antitumor effect, [Key words] metastatic breast cancer; do